See the DrugPatentWatch profile for Adderall
The availability of Adderall is anticipated to remain a concern into 2025, with ongoing supply chain issues impacting production and distribution [1][2]. The primary driver of the shortage is the limited manufacturing capacity of the active pharmaceutical ingredients (APIs) by the two main suppliers [3].
Why is there still a shortage of Adderall?
The current Adderall shortage stems from production limitations, particularly concerning the amphetamine salts that are the core components of the medication [3]. These limitations have been exacerbated by increased demand [2]. The U.S. Drug Enforcement Administration (DEA) has set quotas for the production of these controlled substances, which have historically been insufficient to meet the rising prescription numbers [3].
When will the Adderall shortage end?
There is no definitive end date for the Adderall shortage. While manufacturers are working to increase production, significant improvements in supply may not be fully realized in 2025 [1][2]. The DEA's quota system for amphetamine production is a key factor that influences the pace of recovery [3].
What is causing the Adderall supply issues?
The shortage is largely attributed to the limited production capacity of the two primary API manufacturers for amphetamine salts [3]. These manufacturers face production challenges and cannot meet the full demand from pharmaceutical companies producing the finished Adderall product [3]. Additionally, increased demand for ADHD medications has put further strain on the supply chain [2].
What are the alternatives to Adderall?
For individuals experiencing shortages, healthcare providers may consider alternative medications for ADHD. These can include other stimulant medications like methylphenidate-based drugs (e.g., Ritalin, Concerta) or non-stimulant options such as atomoxetine (Strattera), guanfacine (Intuniv), or clonidine (Kapvay) [4]. The choice of alternative depends on individual patient needs, medical history, and response to treatment [4].
Who controls Adderall production quotas?
The U.S. Drug Enforcement Administration (DEA) sets and enforces annual aggregate production quotas for controlled substances, including the amphetamine APIs used in Adderall [3]. These quotas are intended to limit the overall amount of a substance manufactured in the United States to meet legitimate medical, scientific, research, and industrial needs while preventing diversion and abuse [3].
What is the impact of the Adderall shortage on patients?
Patients prescribed Adderall have faced challenges in obtaining their medication, leading to missed doses, increased anxiety, and difficulties managing ADHD symptoms [1][2]. This can disrupt daily routines, academic performance, and professional productivity [1]. Patients may experience withdrawal symptoms or a resurgence of ADHD symptoms if they cannot access their prescribed treatment [2].
Sources:
[1] https://www.drugpatentwatch.com/adderall-shortage
[2] https://www.drugpatentwatch.com/blog/us-drug-shortages-continue-into-2024-and-beyond
[3] https://www.drugpatentwatch.com/blog/dea-addresses-adderall-shortage
[4] https://www.drugpatentwatch.com/blog/adderall-shortage-what-are-alternatives